Abatacept Sustains Clinical Benefit for Three Years in Rheumatoid Arthritis Patients for Whom Methotrexate is Inadequate

Amsterdam (ots/PRNewswire) - Data presented at the 2006 European
League Against Rheumatism (EULAR) Annual Congress in Amsterdam show
that 3 years of treatment with the selective co-stimulation modulator
abatacept, maintains improvements in Rheumatoid Arthritis (RA)
symptoms, physical function, disease activity and patient and
physician global assessments, in patients with active disease for
whom treatment with methotrexate is inadequate[1]. During the
long-term extension, the abatacept 10mg/kg group maintained the ACR
20, 50 and 70 responses achieved during the first year of treatment,
with almost one third of patients experiencing an ACR 70 at Year 3.

The new data come from a 2-year open-label extension study in
patients who completed a one-year double-blind placebo-controlled
trial of abatacept at a dose of 2 or 10 mg/kg monthly. 219 patients
were treated with abatacept

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | PRN

print